Note to Psychiatrists:®Schizophrenia patients stable (CGI-S <3) on Seroquel®
A global medical research study is being conducted to demonstrate that the efficacy of the sustained release formulation (SR) of Seroquel® is not inferior to the immediate-release formulation (IR), and that stability is maintained when switching from Seroquel® IR to SR.
Benefit to your patient:
A 4-week run-in period will ensure that your patient is clinically stable (dose range of 400 mg to 800 mg/day). Thereafter, the 6-week double-blind phase of the study will begin, where patients will be assigned to treatment either with a fixed dose of quetiapine SR (taken once daily) or IR (taken twice daily).
As part of the study, Seroquel® IR is available for 6 months after the treatment period for patients doing well.
Please contact one of the following investigators for more information: